Ind-Swift gets Japanese approval for pioglitazone and risedronate
This article was originally published in Scrip
Executive Summary
A day after India and Japan inked a broad trade agreement, the Indian company Ind-Swift Laboratories said that it had received approval from Japan's Pharmaceutical and Medical Devices Agency (PMDA) for pioglitazone and risedronate sodium manufactured at its facilities at Derabassi in Punjab.